Differences underlying EGFR and HER2 oncogene addiction

被引：38

作者：

Faber, Anthony C. ^{[1
]}

Wong, Kwok-Kin ^{[2
,3
,4
]}

Engelman, Jeffrey A. ^{[1
,3
]}

机构：

[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA

[2] Harvard Univ, Dana Farber Canc Inst, Ctr Canc, Ludwig Ctr, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Dept Med, Boston, MA USA

[4] Harvard Univ, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

来源：

CELL CYCLE | 2010年 / 9卷 / 05期

关键词：

TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; CANCER; GROWTH;

D O I：

10.4161/cc.9.5.11096

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

引用

页码：851 / 852

页数：2

共 10 条

[1] Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells [J].

Brachmann, Saskia M. ;

Hofmann, Irmgard ;

Schnell, Christian ;

Fritsch, Christine ;

Wee, Susan ;

Lane, Heidi ;

Wang, Shaowen ;

Garcia-Echeverria, Carlos ;

Maira, Sauveur-Michel .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (52) :22299-22304

[2]

CERTO M, 2002, CANCER CELL, V9, P351

[3] Acquired resistance to tyrosine kinase inhibitors during cancer therapy [J].

Engelman, Jeffrey A. ;

Settleman, Jeffrey .

CURRENT OPINION IN GENETICS & DEVELOPMENT, 2008, 18 (01) :73-79

[4] Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer [J].

Engelman, Jeffrey A. ;

Jaenne, Pasi A. .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :2895-2899

[5] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Mitsudomi, Tetsuya ;

Song, Youngchul ;

Hyland, Courtney ;

Park, Joon Oh ;

Lindeman, Neal ;

Gale, Christopher-Michael ;

Zhao, Xiaojun ;

Christensen, James ;

Kosaka, Takayuki ;

Holmes, Alison J. ;

Rogers, Andrew M. ;

Cappuzzo, Federico ;

Mok, Tony ;

Lee, Charles ;

Johnson, Bruce E. ;

Cantley, Lewis C. ;

Janne, Pasi A. .

SCIENCE, 2007, 316 (5827) :1039-1043

[6] Targeting PI3K signalling in cancer: opportunities, challenges and limitations [J].

Engelman, Jeffrey A. .

NATURE REVIEWS CANCER, 2009, 9 (08) :550-562

[7] Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition [J].

Faber, Anthony C. ;

Li, Danan ;

Song, YoungChul ;

Liang, Mei-Chih ;

Yeap, Beow Y. ;

Bronson, Roderick T. ;

Lifshits, Eugene ;

Chen, Zhao ;

Maira, Sauveur-Michel ;

Garcia-Echeverria, Carlos ;

Wong, Kwok-Kin ;

Engelman, Jeffrey A. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (46) :19503-19508

[8] Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function [J].

Luciano, F ;

Jacquel, A ;

Colosetti, P ;

Herrant, M ;

Cagnol, S ;

Pages, G ;

Auberger, P .

ONCOGENE, 2003, 22 (43) :6785-6793

[9] NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations [J].

Serra, Violeta ;

Markman, Ben ;

Scaltriti, Maurizio ;

Eichhorn, Pieter J. A. ;

Valero, Vanesa ;

Guzman, Marta ;

Luisa Botero, Maria ;

Llonch, Elisabeth ;

Atzori, Francesco ;

Di Cosimo, Serena ;

Maira, Michel ;

Garcia-Echeverria, Carlos ;

Lluis Parra, Josep ;

Arribas, Joaquin ;

Baselga, Jose .

CANCER RESEARCH, 2008, 68 (19) :8022-8030

[10] Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling [J].

She, Qing-Bai ;

Chandarlapaty, Sarat ;

Ye, Qing ;

Lobo, Jose ;

Haskell, Kathleen M. ;

Leander, Karen R. ;

DeFeo-Jones, Deborah ;

Huber, Hans E. ;

Rosen, Neal .

PLOS ONE, 2008, 3 (08)

← 1 →